Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer

Huang, Shaojun; Wang, Yufei; Jin, Zhiyong; Sun, Jiayang; Guo, Zhanlin

doi:10.1007/s13277-013-1526-0

Cited by 18 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2013)Asian (China)5438/1656 (30–73)III-IVDDP/CBP-basedORPCR-RFLP XRCC1 rs1799782, RRM1 rs12806698 96 Zhang, Y P. (2013)Asian (China)6238/2458 (37–72)NRDDP+NVB/TAX/GEM/PEMORDirect sequencing XPD rs13181 97 Zhou, G R. (2013)Asian (China)204120/8461 (45–75)NRDDP -basedORMALDI-TOF-MS XRCC1 rs25487 98 Huang, S. J. (2014)Asian (China)187124/63NRIIIA-IVPlatinum-basedOR, OSMALDI-TOF-MS ERCC1 rs11615 rs3212986, rs2298881 99 Zhang, L. (2014)Asian (China)375249/126NRIIIA-IVCBP+NVP+DDP, DDP+DOCOR, OS, PFSSequenom MassARRAY platform XPD rs13181 rs1799793 rs1052555 rs238406, XRCC1 rs25487 rs1799782 100 Jin, Z. Y. (2014)Asian (China)378297/8162.4 (36–78)I-IVDDP+GEM/DOC/NVP/TAXOR, OSPCR-RFLP XPG rs1047768 rs17655 XRCC1 rs25489, XRCC3 rs861539 101 Hu, W. (2014)Asian (China)277184/9363.1 (29–75)IIIA-IVPlatinum-basedOS, PFSPCR-RFLP XPG rs1047768 rs17655 rs2296147 rs873601 102 Peng, Y.…”

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Data regarding genetic polymorphisms and platinum-based chemotherapy (PBC) treatment outcomes in patients with NSCLC are published at a growing pace, but the results are inconsistent. This meta-analysis integrated eligible candidate genes to better evaluate the pharmacogenetics of PBC in NSCLC patients. Relevant studies were retrieved from PubMed, Chinese National Knowledge Infrastructure and WANFANG databases. A total of 111 articles comprising 18,196 subjects were included for this study. The associations of genetic polymorphisms with treatment outcomes of PBC including overall response rate (ORR), overall survival (OS) and progression-free survival (PFS) were determined by analyzing the relative risk (RR), hazard ration (HR), corresponding 95% confidence interval (CI). Eleven polymorphisms in 9 genes, including ERCC1 rs11615 (OS), rs3212986 (ORR), XPA rs1800975 (ORR), XPD rs1052555 (OS, PFS), rs13181 (OS, PFS), XPG rs2296147 (OS), XRCC1 rs1799782 (ORR), XRCC3 rs861539 (ORR), GSTP1 rs1695 (ORR), MTHFR rs1801133 (ORR) and MDR1 rs1045642 (ORR), were found significantly associated with PBC treatment outcomes. These variants were mainly involved in DNA repair (EXCC1, XPA, XPD, XPG, XRCC1 and XRCC3), drug influx and efflux (MDR1), metabolism and detoxification (GSTP1) and DNA synthesis (MTHFR), and might be considered as potential prognostic biomarkers for assessing objective response and progression risk in NSCLC patients receiving platinum-based regimens.

show abstract

Section: Resultsmentioning

confidence: 99%

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Tan

Qiu

Zhu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…However, inconsistent results came from different studies on the same issue. For example, Huang et al and Zhao et al reported that ERCC1 C8092A may be useful predictive markers for response to platinum-based chemotherapy [19, 20], but some other studies showed the contradictory results 21–23]. The same situations were also existed in MDR1 C3435T, XPD A2251C and other SNPs.…”

Section: Introductionmentioning

confidence: 99%

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis

et al. 2016

View full text Add to dashboard Cite

Published data showed inconsistent results about associations of extensively studied polymorphisms with platinum-based chemotherapy response. Our study aimed to provide reliable conclusions of these associations by detecting genotypes of the SNPs in a larger sample size and summarizing a comprehensive pooled analysis. 13 SNPs in 8 genes were genotyped in 1024 NSCLC patients by SequenomMassARRAY. 39 published studies and our study were included in meta-analysis. Patients with GA or GG genotypes of XRCC1 G1196 had better response than AA genotype carriers (Genotyping study: OR = 0.72, 95%CI: 0.53-0.96, P = 0.028; Meta-analysis: OR = 0.74, 95%CI: 0.62-0.89, P = 0.001). Patients carrying CT or TT genotypes of XRCC1 C580T could be more sensitive to platinum-based chemotherapy compared to patients with CC genotype (OR = 0.54, 95%CI: 0.37-0.80, P = 0.002). CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes (OR = 0.69, 95%CI: 0.52-0.91, P = 0.009). Our study indicated that XRCC1 G1196A/C580T and XRCC3 C18067T should be paid attention for personalized platinum-based chemotherapy in NSCLC patients.

show abstract

“…ERCC1, for example, is upregulated in a number of cisplatin-resistant ovarian cancer cell lines [147]. This is complemented by significantly prolonged survival of patients with ERCC1-negative tumors [89].…”

Section: Drug Resistance In Lung Cancermentioning

confidence: 99%

DNA Repair Pathways and their Therapeutic Potential in Lung Cancer

Burgess

Croft

Wallace

et al. 2014

Lung Cancer Manage.

View full text Add to dashboard Cite

practice points• A normal cycling cell can encounter up to 30,000 DNA damage events in 1 day, which are repaired by distinct pathways that target and repair specific lesions.• Platinum-based chemotherapeutics exert toxicity through the formation of irreparable base adducts and DNA crosslinks, which direct the cancerous cells towards apoptotic death.• The selective pressure exerted on the tumor eventuates genetic drift and may provide the cancerous cells resistance to many anticancer therapies.• Several distinct while overlapping pathways exist within the cell to detect and repair the various DNA damage lesions that may occur.• The inaccurate repair of DNA lesions may lead to mutations within the cell and drive tumorigenesis.• Many cancers contain mutations in DNA repair genes, for example, more than 90% of small cell lung cancers and 50% of all non-small-cell lung cancers carry mutations in tP53, encoding the important tumor suppressor, p53.• Many anticancer therapies, including platinum-based chemotherapeutics and replication inhibitors, induce apoptosis within the cell through the formation of irreparable DNA damage.• The deregulation of DNA repair proteins within cells may provide an attractive therapeutic window. Such an approach is exemplified by the PARP inhibitors, which show potential use in the treatment of cancers deficient of functional BRCA1 or BRCA2. In addition, these drugs may show increased efficacy in combination with DNA-damaging agents.• Resistance to platinum-based agents may be acquired through multiple mechanisms, including mutation or deregulation of DNA repair proteins, alteration of membrane transport protein activity and chromatin remodeling.

show abstract

Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer

Cited by 18 publications

References 22 publications

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis

DNA Repair Pathways and their Therapeutic Potential in Lung Cancer

Contact Info

Product

Resources

About